跳转至内容
Merck

Y0000599

咪达唑仑标准液

European Pharmacopoeia (EP) Reference Standard

别名:

Midazolam, 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H13ClFN3
CAS号:
分子量:
325.77
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

midazolam

製造商/商標名

EDQM

藥物控制

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

InChI

1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3

InChI 密鑰

DDLIGBOFAVUZHB-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Midazolam for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbones

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 3 Oral

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

P Jevon
British dental journal, 213(2), 81-82 (2012-07-28)
This article is published in response to a query from reader Sarah Clements, based at Golding House Dental Practice Ltd in Kent, regarding the BDJ paper entitled 'Updated guidance on medical emergencies and resuscitation in the dental practice' (BDJ 2012;
Eleonora L Swart et al.
Current drug metabolism, 13(6), 760-766 (2012-03-29)
A variety of developmental changes is of influence on the pharmacokinetics and pharmacodynamics of midazolam in neonatal and pediatric intensive care patients. However, dosing regimens in children are based upon rather empirical extrapolations from the dosing regimens in adults. Based
Eugene Ng et al.
The Cochrane database of systematic reviews, 6(6), CD002052-CD002052 (2012-06-15)
Proper sedation for neonates undergoing uncomfortable procedures may reduce stress and avoid complications. Midazolam is a short-acting benzodiazepine that is increasingly used in neonatal intensive care units (NICU). However, its effectiveness as a sedative in neonates has not been systematically
Question 3 Ketamine or midazolam: does it matter which?
Elisabeth Jameson
Archives of disease in childhood, 96(1), 106-108 (2010-12-21)
Karly P Garnock-Jones
Paediatric drugs, 14(4), 251-261 (2012-06-19)
Oromucosal midazolam (Buccolam™) is a benzodiazepine approved for the treatment of pediatric patients with acute, prolonged, convulsive seizures. This article reviews the pharmacologic properties of oromucosal midazolam and its clinical efficacy and tolerability for the treatment of prolonged acute convulsive

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门